Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Phase 1

Active, not recruiting

• Conditions: Obesity; Diabetes Mellitus, Type 2
• Interventions: Drug: ENT-03; Drug: Placebo

• Registration Number: NCT05925920
• Lead Sponsor: Metabolics Pharma

Brief Summary

Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-06-05
• Study Start: 2023-06-13
• Study First Submitted QC: 2023-06-22
• Study First Posted: 2023-06-29
• Primary Completion: 2024-08-12
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-31
• Last Update Posted: 2024-11-05
• Study Completion: 2024-12-06

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. Subjects aged 18-70 years, both genders.
2. Healthy as determined by a physician, based on history, medical examination, vital signs, and laboratory tests.
3. Males that agree to use condoms for the duration of participation in the study.
4. Females of non-child-bearing potential (i.e., tubal ligation, hysterectomy, or postmenopausal).
5. Female patients of child-bearing potential with negative serum pregnancy tests and who agree to use double-barrier contraception during the study.
6. Subjects must be able to read, speak, and understand English and/or Spanish and provide written informed consent, and be willing and able to comply with study procedures.
7. Subjects must have a BMI 30-35 kg/m2 inclusive assessed immediately prior to screening.
8. Fasting insulin level ≥11 mIU/L.
9. HbA1c < 8.5% (diabetic subjects only).
10. Subjects with Type 2 diabetes on no anti-diabetic medication or on stable doses of metformin for 4 weeks or more (diabetic cohorts only).
11. No history of active or chronic disease other than that allowed by study: hypertension, hyperlipidemia, hyperglycemia, GERD, heartburn, or Type 2 diabetes (cohorts 6 and 7 only).

Exclusion Criteria

1. History of excessive alcohol use (defined as >21 drinks per week for males and >14 drinks per week for females), recreational drug use within the past three months, or failure on urinary drug screen.

2. Pregnant or breastfeeding within six months of screening assessment.

3. Substantial changes in eating habits or exercise routine within the preceding three months.

4. Evidence of eating disorders.

5. >5% weight change in the past three months.

6. Bariatric surgery within the past five years.

7. Significant renal impairment (eGFR <60 mg/mL/1.73m2).

8. Patients on anti-diabetic medications other than metformin.

9. Patients with gastroparesis.

10. Liver function tests (i.e., ALT, AST, alkaline phosphatase) greater than twice the upper limit of normal upon repeated measurements.

11. Diseases interfering with metabolism and/or ingestive behavior (e.g., myxedema, Cushing's disease, schizophrenia, major psychoses).

12. History of major depressive disorder within the previous two years, a lifetime history of suicide attempt, suicidal behavior within the previous month, or history of other severe psychiatric disorders.

13. Score of >15 on the Columbia Suicide Severity Rating Scale (C-SSRS).

14. Use of medications affecting body weight within the past three months:

    • Drugs approved for the treatment of obesity
    • Cyproheptadine or medroxyprogesterone
    • Atypical anti-psychotic drugs
    • Tricyclic antidepressants
    • Lithium, MAO's, glucocorticoids
    • SSRI's or SNRI's
    • Antiepileptic drugs

15. Any clinically significant abnormality following the Investigator's review of the physical examination and clinical laboratory tests.

16. A baseline prolongation of QT/QTc interval after repeated measurements of >450 ms; a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).

17. Participation in an investigational drug trial within the month prior to dosing in the present study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Active	ENT-03	Receive a single dose of ENT-03 sub-cutaneously
Placebo	Placebo	Receive a single dose of placebo sub-cutaneously

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability of ENT-03	7 days	Vital signs: body weight in kilograms
Safety and tolerability of ENT-03	7 days	Adverse Events

Secondary Outcome Measures

Name	Time	Method
pharmacokinetic endpoints: maximum plasma concentration	pre-dose, 24 hours, 48 house, 72 hours	maximum measured plasma concentration
pharmacokinetic endpoints: time of maximum plasma concentration	pre-dose, 24 hours, 48 house, 72 hours	time of maximum measured plasma concentration
pharmacokinetic endpoints: ENT-03 half-life	pre-dose, 24 hours, 48 house, 72 hours	terminal elimination of ENT-03 half-life in plasma
pharmacokinetic endpoints: plasma concentration	pre-dose, 24 hours, 48 house, 72 hours	area under the concentration versus time curve over 24 hours
pharmacokinetic endpoint: ENT-03 clearance	pre-dose, 24 hours, 48 house, 72 hours	Clearance of ENT-03
pharmacokinetic endpoint: elimination phase	pre-dose, 24 hours, 48 house, 72 hours	slope of terminal elimination phase
pharmacodynamic endpoint: glucose	7 days	change from screening visit in fasting plasma glucose
pharmacodynamic endpoint: insulin	7 days	change from screening visit in fasting serum insulin
pharmacodynamic endpoint: fasting lipids	7 days	change from screening visit in fasting lipids
pharmacodynamic endpoint: fasting leptin	7 days	change from screening visit in fasting leptin
pharmacodynamic endpoint: body weight	7 days	change from screening visit in body weight (kg)
effect on glucose	Days -7, 2, 3, 4, and 7	results of fasting and post-prandial blood glucose in subjects with obesity and T2D
effect on insulin and insulin sensitivity	Days -7, 2, 3, 4, and 7	results of fasting and post-prandial blood insulin and insulin sensitivity as measured by homeostatic assessment of insulin resistance (HOMAIR), in subjects with obesity and T2D

Trial Locations

Locations (1)

ProSciento; 🇺🇸 San Diego, California, United States